Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2977–3000 of 121,474 matching trials from the live ClinicalTrials.gov search.

Filters: Completed Clear all

Conditions: Schizophrenia
Interventions: Folic Acid, Placebo; Dietary Supplement · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 90 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Interventions: Asparaginase, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 1,895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2025
U.S. locations: 191
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more

Conditions: Renal Cell Carcinoma (RCC)
Interventions: Pembrolizumab, Epacadostat, Sunitinib, Pazopanib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 25
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 19 more

Conditions: Hypertension
Interventions: Automated Telephone Program, Health Behavior Education; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 35 Years and older
Enrollment: 337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ); Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 5
States / cities: Little Rock, Arkansas • South Miami, Florida • Mattapan, Massachusetts + 2 more

Conditions: Frailty, Inflammation
Interventions: Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C); Drug
Lead sponsor: University of Rochester; Other
Eligibility: 65 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: etanercept, arsenic trioxide; Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy Volunteer
Interventions: Treatment A: PCI-32765, Treatment B: PCI-32765; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Advanced Solid Tumors
Interventions: TAS-102, Trifluridine; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Critically Ill Mechanically Ventilated Subjects
Interventions: Peptamen Bariatric, Replete; Other
Lead sponsor: Société des Produits Nestlé (SPN); Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Atlanta, Georgia • Chicago, Illinois • Lexington, Kentucky + 3 more

Conditions: ADHD, Parenting
Interventions: Behavioral Parent Training, Extended release mixed amphetamine salts (MAS); Behavioral · Drug
Lead sponsor: University of Maryland, College Park; Other
Eligibility: 3 Years to 65 Years
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: College Park, Maryland

Conditions: Small Bowel Crohn's Disease
Interventions: Filgotinib, Placebo to match filgotinib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 15
States / cities: Miami, Florida • Orlando, Florida • Tampa, Florida + 12 more

Conditions: Cavity, Cavities of Teeth
Interventions: Composite with 90 degree cavosurface angle, Composite with wide bevel; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Myopia
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 8 Years to 11 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Chronic Post-Traumatic Stress Disorder
Interventions: Intervention Training, Control Condition; Behavioral
Lead sponsor: Morehouse School of Medicine; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Acute Mountain Sickness (AMS)
Interventions: T89 capsule, Placebo capsule; Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 853 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Scars, Hypertrophic
Interventions: Treatment of hypertrophic scars (Soliton's Rapid Acoustic Pulse (RAP) Device); Device
Lead sponsor: Soliton; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Chronic Kidney Diseases
Interventions: Dietary education program; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: busulfan, cyclophosphamide, autologous hematopoietic stem cell transplantation; Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy
Interventions: Cohort A, Cohort B, Cohort C, Cohort D; Biological
Lead sponsor: Uniquity One (UNI); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Advanced Solid Tumours, Small Cell Lung Cancer
Interventions: IMP4297(senaparib); Drug
Lead sponsor: Impact Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Evergreen Park, Illinois • Canton, Ohio • Columbus, Ohio + 1 more

Conditions: Dystonia, Focal Hand Dystonia, FHD
Interventions: Transcranial Electrical Polarization (TEP); Procedure
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sleep, Consolidation
Interventions: Targeted memory reactivation (sounds); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Videolaryngoscopes (VL), Direct Laryngoscopy (DL), Inexperienced Users
Interventions: Miller, Macintosh, C-MAC, GlideScope; Device
Lead sponsor: Joseph D. Tobias; Other
Eligibility: Not listed
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Interactive Multirisk-Factor Intervention for Hypertension (HTN) Blacks

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension

Reducing Frailty for Older Cancer Survivors Using Supplements

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

The DIVINE Study: DIetary Management of Glucose VarIability iN thE ICU

Treating Parents With ADHD and Their Young Children Via Telehealth: A Hybrid Type I Effectiveness-Implementation Trial

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)

In Vivo Assessment of the Tooth-Resin Composite Interface Using Optical Coherence Tomography

The Contact Lens and Myopia Progression (CLAMP) Study

G.R.I.T. - Goal-directed Resilience Intervention Training

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Treatment of Fibrotic Scars With Rapid Acoustic Pulse (RAP) Device

Effects of a Whole-food, Plant-based Nutrition Program on BP and Potassium in Subjects With CKD

Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants

IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

Transcranial Electrical Polarization to Treat Focal Hand Dystonia

Reinstatement of Context During Sleep and Its Subsequent Effect on Memory: an fMRI Study

VL vs DL in Inexperienced Users: a Pediatric Manikin Study